Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA7 | P43166 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502459 | 1.00 | CYP1A2 (0.42) | CYP1A2MMP8IRAK4PIN1CNR2 | |
| SCHEMBL4540451 | 0.85 | CYP1A2 (0.41) | CYP1A2MMP8IRAK4PIN1PPARA | |
| SCHEMBL3211508 | 0.84 | CYP1A2 (0.41) | CYP1A2MMP8PIN1TSHRCA12 | |
| SCHEMBL29987624 | 0.84 | CYP1A2 (0.41) | CYP1A2MMP8PIN1TSHRCA12 | |
| SCHEMBL898182 | 0.84 | CYP1A2 (0.41) | CYP1A2MMP8PIN1CNR2MAOB | |
| SCHEMBL21940678 | 0.83 | PLCG1 (0.39) | CYP1A2IRAK4CNR2MAPTALDH1A1 | |
| SCHEMBL30496866 | 0.83 | PLCG1 (0.39) | CYP1A2IRAK4CNR2MAPTALDH1A1 | |
| SCHEMBL10322716 | 0.82 | CYP1A2 (0.41) | CYP1A2MMP8PIN1PPARATSHR | |
| SCHEMBL23582234 | 0.82 | MAPT (0.46) | CYP1A2MMP8PIN1CNR2MAOB | |
| SCHEMBL31357620 | 0.82 | MAPT (0.46) | CYP1A2MMP8PIN1CNR2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4561991-A1 | NOVEL HETEROCYCLES AS SPLA2-X INHIBITORS | Cayman Chemical Company, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-111868051-B | Aminopyrimidine derivatives as CTPS1 inhibitors | 斯泰普制药股份公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2024026290-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | CAYMAN CHEMICAL COMPANY INCORPORATED (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7935708-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2011-05-03 | — | — | US | disclosed |
| US-7834019-B2 | Substituted pyrazolo[3,4-d]pyrimidinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-2016080-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2010-07-28 | — | — | EP | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| EP-2016080-A4 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | EP | disclosed |
| CN-101432284-A | Dihydropyrazolopyrimidinone derivative | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| EP-2016080-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007126122-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-11-08 | — | — | WO | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | CYP1A2 4592/4885MMP8 4296/4885IRAK4 3/4885 |
| US-20260034111-A1 | NOVEL HETEROCYCLES AS sPLA2-X INHIBITORS | PLA2G2F, PLA2R1, PLA2G12A | CYP1A2 1230/4885MMP8 416/4885IRAK4 3244/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | CYP1A2 2456/4885MMP8 3185/4885IRAK4 3/4885 |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | CYP1A2 726/4885MMP8 2587/4885IRAK4 502/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | CYP1A2 1040/4885MMP8 3942/4885IRAK4 523/4885 |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | CYP1A2 168/4885MMP8 4307/4885IRAK4 3477/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CYP1A2 3570/4885MMP8 901/4885IRAK4 4/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | CYP1A2 1040/4885MMP8 3942/4885IRAK4 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.